









Markets
/
Stocks
/
nasdaq-mrsn
/

Mersana Therapeutics Inc

MRSN

8.460USD

+0.300+3.68%

Close 11/05, 16:00（ET）Quotes delayed by 15 min

42.22MMarket Cap

LossP/E TTM



Mersana Therapeutics Inc

8.460

+0.300+3.68%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

Overview

Company

Financials

Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score of Mersana Therapeutics Inc

Currency: USD Updated: 2025-11-05

Key Insights

The company's fundamentals are relatively healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong technicals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Mersana Therapeutics Inc's Score

Industry at a Glance

Industry Ranking

118 / 407

Overall Ranking

249 / 4616

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 9 analysts

Buy

Current Rating

72.857

Target Price

+792.86%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Mersana Therapeutics Inc Highlights

StrengthsRisks

Mersana Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which is focused on the development of antibody-drug conjugates (ADCs), which offer a clinically meaningful benefit for cancer patients with significant unmet needs. It has developed two proprietary and differentiated ADC platforms: Dolasynthen and Immunosynthen. Dolasynthen is its cytotoxic ADC platform that is designed to generate site-specific, homogeneous ADCs. Immunosynthen is its proprietary stimulator of interferon genes (STING)-agonist platform that is designed to generate systemically administered ADCs that locally activate STING signaling in both antigen-expressing tumor cells and in tumor-resident immune cells. The Company's pipeline also includes XMT-1660, a Dolasynthen ADC targeting B7-H4 in a Phase I clinical trial, and XMT-2056, an Immunosynthen ADC targeting a novel epitope of human epidermal growth factor receptor 2 (HER2), in addition to other earlier-stage assets.

High Growth

The company's revenue has grown steadily over the past 3 years, averaging 52.35% year-on-year.

Growing

The company is in a growing phase, with the latest annual income totaling USD 40.50M.

Undervalued

The company’s latest PE is -0.57, at a low 3-year percentile range.

Institutional Selling

The latest institutional holdings are 3.07M shares, decreasing 45.86% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 114.01K shares of this stock.

Lower Market Activity

The company has less investor interest, with a 20-day turnover ratio of -0.96.

Financial Health

Currency: USD Updated: 2025-11-05

The company's current financial score is 5.81, which is lower than the Biotechnology & Medical Research industry's average of 6.92. Its financial status is stable, and its operating efficiency is low. Its latest quarterly revenue reached 3.06M, representing a year-over-year increase of 33.28%, while its net profit experienced a year-over-year increase of 0.12%.

Score

Industry at a Glance

Previous score

5.81

Change



Financials

6.14

Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings

7.63

Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency

2.57

Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential

5.58

Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns

7.11

Key Metrics

Free cash flow

No Data

Mersana Therapeutics Inc's Company Valuation

Currency: USD Updated: 2025-11-05

The company’s current valuation score is 7.29, which is higher than the Biotechnology & Medical Research industry's average of 7.05. Its current P/E ratio is -0.57, which is -96.94% below the recent high of -0.02 and -25.18% above the recent low of -0.71.

Score

Industry at a Glance

Previous score

7.29

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 118/407

No Data

Earnings Forecast

Currency: USD Updated: 2025-11-05

The company’s current earnings forecast score is 8.89, which is higher than the Biotechnology & Medical Research industry's average of 8.00. The average price target for Mersana Therapeutics Inc is 36.00, with a high of 325.00 and a low of 8.00.

Score

Industry at a Glance

Previous score

8.89

Change

Support & Resistance

No Data

Analyst Rating

Based on 9 analysts

Buy

Current Rating

72.857

Target Price

+792.86%

Upside Space

Strong Buy

Buy

Hold

Sell

Strong Sell

Peer Comparison

521

Total

Median

Average

Company name

Ratings

Analysts

Mersana Therapeutics Inc

MRSN

CRISPR Therapeutics AG

CRSP

Ionis Pharmaceuticals Inc

IONS

argenx SE

ARGX

Intellia Therapeutics Inc

NTLA

IQVIA Holdings Inc

IQV

...

104

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-11-05

The company’s current price momentum score is 6.80, which is higher than the Biotechnology & Medical Research industry's average of 6.49. Sideways: Currently, the stock price is trading between the resistance level at 10.41 and the support level at 7.26, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

6.73

Change

0.07

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(3)

Neutral(2)

Buy(1)

Indicators

Value

Direction

MACD(12,26,9)

-0.555

Neutral

RSI(14)

44.258

Neutral

STOCH(KDJ)(9,3,3)

19.956

Sell

ATR(14)

0.737

Low Volatility

CCI(14)

-167.681

Sell

Williams %R

83.363

Oversold

TRIX(12,20)

0.515

Sell

StochRSI(14)

23.796

Buy

Moving Average

Sell(3)

Neutral(0)

Buy(3)

Indicators

Value

Direction

MA5

8.988

Sell

MA10

9.492

Sell

MA20

9.702

Sell

MA50

8.389

Buy

MA100

5.829

Buy

MA200

3.135

Buy

Institutional Confidence

Currency: USD Updated: 2025-11-05

The company’s current institutional recognition score is 5.00, which is lower than the Biotechnology & Medical Research industry's average of 5.16. The latest institutional shareholding proportion is 61.59%, representing a quarter-over-quarter decrease of 14.11%. The largest institutional shareholder is The Vanguard, holding a total of 307.14K shares, representing 6.15% of shares outstanding, with 0.85% increase in holdings.

Score

Industry at a Glance

Previous score

5.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Nextech Invest, Ltd.

482.69K

Bain Capital Life Sciences Investors, LLC

346.55K

The Vanguard Group, Inc.

Star Investors

307.14K

-8.35%

Schonfeld Strategic Advisors LLC

226.95K

-25.48%

AQR Capital Management, LLC

205.19K

-0.27%

Rock Springs Capital Management LP

152.59K

BlackRock Institutional Trust Company, N.A.

142.35K

-52.14%

SilverArc Capital Management, LLC

125.14K

+1.29%

Acadian Asset Management LLC

118.21K

-1.15%

Renaissance Technologies LLC

Star Investors

114.01K

+239.34%

Risk Assessment

Currency: USD Updated: 2025-11-05

The company’s current risk assessment score is 1.45, which is lower than the Biotechnology & Medical Research industry's average of 3.47. The company's beta value is 0.91. This indicates that the stock tends to underperform the index during upward trending markets but experiences smaller declines during downward trending markets.